Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Income from Continuing Operations (2022 - 2025)

Oramed Pharmaceuticals' Income from Continuing Operations history spans 4 years, with the latest figure at 72920000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations changed N/A year-over-year to 72920000.0; the TTM value through Dec 2025 reached 126927000.0, changed N/A, while the annual FY2025 figure was 64016000.0, 435.11% up from the prior year.
  • Income from Continuing Operations reached 72920000.0 in Q4 2025 per ORMP's latest filing, up from 48389000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 72920000.0 in Q4 2025 to a low of 19642000.0 in Q3 2024.
  • Average Income from Continuing Operations over 4 years is 5289133.33, with a median of 3284000.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 800.99% in 2024, then crashed 598.17% in 2025.
  • A 4-year view of Income from Continuing Operations shows it stood at 12255000.0 in 2022, then skyrocketed by 208.49% to 13296000.0 in 2023, then plummeted by 247.73% to 19642000.0 in 2024, then skyrocketed by 471.25% to 72920000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Income from Continuing Operations are 72920000.0 (Q4 2025), 48389000.0 (Q3 2025), and 13260000.0 (Q2 2025).